Skip to content

US · ASBP · BIOTECHNOLOGY

Aspire Biopharma Holdings, Inc. (ASBP) intrinsic value and stock valuation

$7.13as of 2026-11-21 · Mkt cap 837.6K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aspire Biopharma Holdings, Inc. DCF and intrinsic value

InvestorsCraft values ASBP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ASBP’s statements →

Aspire Biopharma Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Estero, FL 33928 aspirebiolabs.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$10K
20212025
Net income
-$-24.48M
20212025
Free cash flow
-$-4.92M
20212025
Total equity
-$-6.38M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$10K$0.00$0.00$0.00$0.00
Operating income-$-19.35M-$-3.09M-$-1.34M-$-980K-$-30K
Net income-$-24.48M-$-12.54M$4.46M$3.34M-$-30K
EPSd-$-16.43M-$-18.17M$9.29M$3.71M-$-44.12K
Operating cash flow-$-4.92M-$-270K-$-650K-$-1.41M-$0.00
Capital expenditure$0.00$0.00-$0.00-$0.00$0.00
Free cash flow-$-4.92M-$-270K-$-650K-$-1.41M-$0.00
Total assets$1.31M$150K$20M$300.2M$290K
Total debt$1.38M$1.27M$10K$30K$240K
Net debt$380K$1.26M$10K-$-500K$240K
Total equity-$-6.38M-$-1.54M$19.6M$289.1M-$0.00
Cash and short-term investments$1M$0.00$10K$500K$0.00
Income statement
20252024202320222021
Revenue$10K$0.00$0.00$0.00$0.00
Cost of revenue$10K$0.00$0.00$0.00$0.00
Gross profit-$0.00$0.00$0.00$0.00$0.00
Research and development expenses$920K$140K$70K$180K$0.00
Selling, general and administrative expenses$18.4M$3.09M$1.34M$980K$30K
Other expenses$0.00-$-140K-$-70K-$-180K-$0.00
Operating expenses$19.4M$3.09M$1.34M$980K$30K
Cost and expenses$19.4M$3.09M$1.34M$980K$30K
Interest income$0.00$550K$5.81M$4.32M$0.00
Interest expense$8.53M-$-890K$10K$0.00$0.00
Depreciation and amortization$8.02M$0.00$1.34M$0.00$30K
Ebitda-$-11.33M-$-11.65M$5.8M$3.34M-$-30K
Operating income-$-19.35M-$-3.09M-$-1.34M-$-980K-$-30K
Total other income/expenses, net-$-5.13M-$-9.45M$5.8M$4.32M$0.00
Income before tax-$-24.48M-$-12.54M$4.46M$3.34M-$-30K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-24.48M-$-12.54M$4.46M$3.34M-$-30K
Weighted average shares outstanding$1.49M$690K$480K$900K$680K
Weighted average diluted shares outstanding$1.49M$690K$480K$900K$680K
Balance sheet
20252024202320222021
Cash and short-term investments$1M$0.00$10K$500K$0.00
Net receivables$0.00$40K$0.00$0.00$0.00
Inventory$250K$0.00$0.00$0.00$0.00
Total current assets$1.31M$150K$80K$1.1M$290K
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$6.67M$19.9M$300K$0.00
Total non-current assets$0.00$6.67M$19.9M$299.1M$290K
Total assets$1.31M$150K$20M$300.2M$290K
Accounts payable$1.01M$310K$150K$180K$0.00
Short-term debt$1.38M$1.27M$10K$30K$240K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.59M$1.69M$400K$300K$290K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$100K$0.00$0.00$10.8M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$7.69M$1.69M$400K$11.1M$290K
Common stock$0.00$170K$19.9M$299M$0.00
Retained earnings-$-27.26M-$-2.78M-$-11.29M-$-9.94M-$-30K
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-6.38M-$-1.54M$19.6M$289.1M-$0.00
Total investments$0.00$6.67M$19.9M$300K$0.00
Total debt$1.38M$1.27M$10K$30K$240K
Net debt$380K$1.26M$10K-$-500K$240K
Cash flow statement
20252024202320222021
Net income-$-24.48M-$-1.31M$4.46M$3.34M-$0.00
Depreciation and amortization$8.02M$0.00$0.00$0.00$0.00
Stock-based compensation$14.1M$0.00$0.00$0.00$0.00
Change in working capital$530K$1.03M$690K-$-430K-$0.00
Accounts receivable$0.00-$-40K$0.00$0.00$0.00
Inventory-$-250K$0.00$0.00$0.00$0.00
Accounts payable-$-320K$0.00-$-30K$130K$0.00
Net cash provided by operating activities-$-4.92M-$-270K-$-650K-$-1.41M-$0.00
Investments in property, plant and equipment$0.00$0.00$0.00-$-4.9M$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$284.9M-$-294.69M$0.00
Common stock issued$270K$340K$0.00$297.1M$0.00
Common stock repurchased$0.00-$-13.78M-$-284.92M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$5.92M$260K-$-284.76M$296.6M$0.00
Net change in cash$1M-$-10K-$-500K$500K$0.00
Cash at end of period$1M$0.00$10K$500K$0.00
Operating cash flow-$-4.92M-$-270K-$-650K-$-1.41M-$0.00
Capital expenditure$0.00$0.00-$0.00-$0.00$0.00
Free cash flow-$-4.92M-$-270K-$-650K-$-1.41M-$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aspire Biopharma Holdings, Inc.

        Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.

        CEO
        Kraig T. Higginson
        Employees
        2
        Beta
        0.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Aspire Biopharma Holdings, Inc. (ASBP)?

        InvestorsCraft does not currently publish an intrinsic value for ASBP. How the IC value is calculated.

        Is ASBP undervalued?

        InvestorsCraft does not publish an undervaluation signal for ASBP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.